Urolog. pro Praxi, 2006; 2: 52-54

Farmakologická léčba stresové inkontinence

MUDr. Jan Krhut
Urologické oddělení FNsP Ostrava

Urinary incontinence is one of the most common medical conditions with an estimated 25 percent of the adult female population being affected. While overactive bladder is traditionally managed by pharmacotherapy, medication therapy in stress incontinence is of secondary importance. The options to clinically use alpha-adrenergic agents are limited by serious systemic adverse effects. The latest knowledge on physiology and pathophysiology of neural control of the closure apparatus function suggests, however, that pharmacotherapy might even be of use in this area.

Keywords: urinary incontinence, closure pressure, continence mechanism, urethral sphincter, serotonin, noradrenaline

Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krhut J. Farmakologická léčba stresové inkontinence. Urol. praxi. 2006;7(2):52-54.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61(1): 37. Go to original source... Go to PubMed...
    2. Andrew J, Nathan PW: Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. Brain 1964; 87: 233. Go to original source... Go to PubMed...
    3. Ashburn TT, Thor KB: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3(8): 673. Go to original source... Go to PubMed...
    4. Awad SA, Downie JW, Kiruluta HG: Alpha -adrenergic agents in urinary disorders of the proximal urethra. Part 1. Sphincteric incontinence. Brit J Urol 1978; 50: 332. Go to original source... Go to PubMed...
    5. Diokno A, Taub M. Ephedrine in treatment of urinary incontinence. Urology 1975; 5: 624. Go to original source... Go to PubMed...
    6. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003; 170(4 Pt 1): 1259. Go to original source... Go to PubMed...
    7. Fantl JA, Cardozzo L, McClish DK: Estrogen therapy in the managament of urinary incontinence in postmenopausal women: A metaanalysis. First report of the Hormones and urogenital therapy committee. Obstet Gynecol 1994, 83: 12. Go to PubMed...
    8. Füsgen I: Inkontinenz - was bedeutet das für den Betroffenen, für die Gesellschaft und für das Gesundheitswesen? J Urol Urogynecol 1996; 1: 6.
    9. Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC; Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group: A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005; 173(5): 1647. Go to original source... Go to PubMed...
    10. Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW. Prevalence and natural history of female incontinence. Eur Urol 1997; 32 Suppl 2: 3.
    11. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol. 2000; 53(11): 1150. Go to original source... Go to PubMed...
    12. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004 Mar; 63(3): 461-5. Go to original source... Go to PubMed...
    13. Iosif CS, Batra S, Anders E. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981; 141: 817. Go to original source... Go to PubMed...
    14. Kieswetter H, Hennrich F, Englisch M. Clinical and pharmacologic therapy of stress incontinence. Urol Int 1983; 38: 58. Go to original source... Go to PubMed...
    15. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine UI Study Group: Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004; 93(3): 311. Go to original source... Go to PubMed...
    16. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group: Duloxetine versus placebo in the treatment of stres s urinary incontinence. Am J Obstet Gynecol 2002; 187(1): 40. Go to original source... Go to PubMed...
    17. Rashbaum M, Mandelbaum CC. Non-operative treatment of urinary incontinence in women. Am J Obstet Gynaecol 1948; 56: 777. Go to original source... Go to PubMed...
    18. Rud T. Urethral profile in continent women from childhood to old age. Acta Obstet Gynecol Scand 1980; 59: 331. Go to original source... Go to PubMed...
    19. Thor K. Serotonin and Norepinephrine involvement in efferent pathways to the urethral Rhabdosphincter: Implication for treating stress urinary incontinence. Urology 2003; 62 (Suppl 4A): 3. Go to original source... Go to PubMed...
    20. van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndaele JJ, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111(3): 249. Go to original source... Go to PubMed...
    21. Versi E, Cardozo LD. Estrogens and lower urinary tract function. In Studd JWW, Whitehead MI (eds): The Menopause. Oxford, Blackwell Scientific, 1988, p. 76.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.